Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of chronic moderate-to-severe atopic dermatitis (AD) for at least 1 year~* Recent history of inadequate response to medicated topical therapy for AD or required systemic therapy to control disease~* Moderate-to-severe AD defined as affected BSA at least 10%, IGA at least 3, EASI at least 16, Peak Pruritus NRS at least 4~Exclusion Criteria:~* A current or past medical history of conditions associated with thrombocytopenia, coagulopathy, or platelet dysfunction~* Currently have active forms of other inflammatory skin diseases, i.e. not AD, or have evidence of skin conditions (e.g. psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that would interfere with evaluation of AD or response to treatment~* Participants who have received prior treatment with any systemic JAK inhibitors~* Require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication within specified time frames prior to the first dose of study medication, including topical treatments that could affect AD~* Pregnant or breastfeeding women or sexually-active women of childbearing potential who are unwilling to use contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-04965842 200 mg (Type: EXPERIMENTAL): None
- PF-04965842 100 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).